{"product_id":"dxcm-bcg-matrix","title":"(DXCM) DexCom, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis DexCom, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G7 flagship CGM, 10-day wear\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom G7 is DexCom, Inc.’s flagship and main growth engine: the 10-day CGM helped drive 2024 revenue to about $4.03 billion, up 11% year over year. In a CGM market growing at roughly mid-teens CAGR, G7’s rising adoption and strong share fit the \"Star\" profile: high growth, high leadership. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStelo OTC CGM, launched in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStelo is DexCom’s first over-the-counter CGM, launched in 2024, and it fits the Stars quadrant because it opens a new adult consumer channel beyond insulin users. In DexCom’s 2025 growth story, total revenue reached about $4.0 billion, showing the scale to fund this push. The CGM market is still early, so adoption can lift volumes fast if repeat use holds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eG7 sensor consumables, recurring revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom’s G7 is a Stars asset because each user buys a new 10-day sensor again and again, so every install keeps pulling consumables revenue. In 2024, DexCom posted $4.03 billion of revenue, and its growth still leaned on CGM use expanding across the installed base. The model is high-share and high-growth because sensor replacement drives repeat demand, not one-time device sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. CGM franchise for type 2 and MDI users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom’s U.S. CGM franchise for type 2 and MDI users is a Stars business: it taps a much bigger pool than type 1 alone, and DexCom says it serves more than 4 million users worldwide. In 2024, the Company generated about $4.0 billion in revenue, with U.S. prescription and endocrinology channels staying the core route to win new type 2 and MDI patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge pool: type 2 and MDI users.\u003c\/li\u003e\n\u003cli\u003eStrong fit in endocrinology clinics.\u003c\/li\u003e\n\u003cli\u003ePrescription channel supports scale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational G7 rollouts, reimbursement expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom’s international G7 rollout is a real Stars driver: the same CGM platform can scale across new countries with low product change, while payer wins expand access. FY2024 revenue was $4.03 billion, and non-U.S. expansion keeps adding runway as more health systems reimburse continuous glucose monitoring. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame core product, easier scale\u003c\/li\u003e\n\u003cli\u003eNew launches expand addressable markets\u003c\/li\u003e\n\u003cli\u003ePayer coverage lifts adoption and repeat use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWith each new reimbursement decision, DexCom can convert brand reach into share faster outside the United States. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexCom’s G7 and Stelo Power Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom, Inc.’s Stars are G7 and Stelo: 2024 revenue was about $4.03 billion, up 11%, and 2025 revenue was about $4.0 billion. G7 keeps growing in the high-growth CGM market, and Stelo adds a new OTC path beyond insulin users. That mix supports high share and repeat sensor demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025\/2024\u003c\/th\u003e\n\u003cth\u003eStar signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7\u003c\/td\u003e\n\u003ctd\u003e$4.03B revenue\u003c\/td\u003e\n\u003ctd\u003eRepeat 10-day sensor sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelo\u003c\/td\u003e\n\u003ctd\u003eLaunched 2024\u003c\/td\u003e\n\u003ctd\u003eNew OTC growth channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDexCom’s BCG Matrix maps CGM units by growth and share, showing where to invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClean BCG Matrix view of DexCom’s business units to simplify portfolio decisions and spot growth vs. cash cows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists trusted sources behind DexCom, Inc. claims to boost credibility and support faster, better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G6 installed base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom G6 is an older flagship with a large installed user base, so it still anchors recurring sensor and transmitter revenue. With DexCom reporting 2024 revenue of $4.03 billion, the G6 base sits in a more mature, slower-growth phase than G7. That mix of scale, retention, and lower growth fits a classic Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom Share remote monitoring platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom Share is a mature add-on to Dexcom G7 and G6, built for caregivers and families, not for opening a new market. It monetizes the installed CGM base, so its cash flow is steady and tied to recurring sensor use.\u003c\/p\u003e\n\u003cp\u003eDexCom reported 2025 revenue at about $4.0 billion, and the Share platform helps keep that base engaged by making glucose data easier to follow in real time. That makes it a cash cow in the BCG Matrix: low-growth, high-retention, and supported by existing users.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom Clarity diabetes data software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom Clarity supports glucose trend reporting and provider review for the installed CGM base, so it needs little extra sales spend. DexCom reported 2024 revenue of $4.03 billion, and Clarity helps monetize that base with low incremental cost. That makes it a steady cash cow inside the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDexcom Real-Time API developer platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom Real-Time API fits the Cash Cows box: it monetizes the installed CGM base through third-party digital health links, while avoiding the heavy launch cycle of new hardware. DexCom reported 2024 revenue of $4.03 billion, showing a large recurring user base that can support steadier API demand than newer product lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonetizes data, not devices.\u003c\/li\u003e\n\u003cli\u003eUses the installed CGM ecosystem.\u003c\/li\u003e\n\u003cli\u003eGrowth is steadier and more mature.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRecurring replacement sensors and transmitters from legacy users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecurring replacement sensors and transmitters from legacy users are a cash cow because the installed base is already in place, so each refill drives repeat sales with little new customer cost. DexCom’s 2024 revenue was about $4.0 billion, and this replenishment stream helps turn that scale into cash. One user base, many repeat orders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base drives repeat revenue\u003c\/li\u003e\n\u003cli\u003eLow acquisition cost, high share\u003c\/li\u003e\n\u003cli\u003eReplenishment supports cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexCom’s Cash Cows: Turning G6 Users Into Steady Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom’s Cash Cows are the mature, repeat-use layers of the CGM base: G6, Share, Clarity, and refill sensors\/transmitters. DexCom reported 2025 revenue of about $4.0 billion, and these products keep turning the installed user base into steady cash with low extra selling cost.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eG6\u003c\/td\u003e\n\u003ctd\u003eInstalled base\u003c\/td\u003e\n\u003ctd\u003e$4.0B rev\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eDexCom, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe DexCom, Inc. BCG Matrix preview you see is the exact same document you’ll receive after purchase. No sample pages, no watermarks—just the complete, ready-to-use report. Download the full file instantly and use it for analysis, presentations, or strategic planning. What you preview here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G5 Mobile legacy system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom G5 Mobile is an aging CGM platform, first cleared in 2015, and it has been overtaken by G6 and G7. By end-2025, it fits the Dogs bucket: low growth, limited upgrade demand, and likely shrinking revenue mix versus DexCom’s newer systems. Older hardware plus weaker pull from a 2-generation-old platform makes G5 a clear legacy SKU.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G4 Platinum legacy platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom G4 Platinum is a prior-generation CGM and now fits the Dog profile because it no longer drives meaningful growth. DexCom's growth now comes from newer systems, while legacy hardware is largely out of the main revenue engine. In BCG terms, G4 Platinum has low market share and low growth, so it is best treated as a harvest or phase-out asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom SEVEN Plus legacy CGM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom SEVEN Plus is a legacy CGM from DexCom, Inc.’s older product cycle, so it has little role in today’s growth markets. As a discontinued product, it fits the Dogs box: weak strategic value, no real growth, and no meaningful revenue tailwind versus newer systems like Dexcom G7.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy receiver hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy receiver hardware is a Dogs unit for DexCom, Inc.: standalone receiver-first CGM use has been displaced by smartphone-connected workflows, so demand is smaller than for current app-based systems and growth is weak. DexCom does not separately report receiver revenue, but its 2025 focus remained on connected CGM platforms, leaving legacy hardware with limited share and fading strategic value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReceiver-first use is being phased out.\u003c\/li\u003e\n\u003cli\u003eApp-connected CGM drives current demand.\u003c\/li\u003e\n\u003cli\u003eShare is small, growth is weak.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVerily blood-based glucose monitoring collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Verily blood-based glucose monitoring collaboration has not turned into a major commercial line for DexCom, and no standalone revenue has been disclosed from it. By contrast, DexCom’s core CGM business generated about $4.0 billion in 2024 revenue, so the Verily effort has not matched the scale or momentum of the main franchise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 disclosed standalone revenue\u003c\/li\u003e\n\u003cli\u003eNot a market leader\u003c\/li\u003e\n\u003cli\u003eFar smaller than $4.0B CGM core\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWith no clear commercial lead and limited visible traction, the collaboration fits the BCG Dog profile: low share, weak scale, and little impact on DexCom’s growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexCom’s Legacy Dogs Are Fading Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom’s Dogs are legacy lines with little growth and fading share: G5 Mobile, G4 Platinum, SEVEN Plus, and receiver-first hardware. The Verily glucose project also shows weak traction, with no standalone revenue disclosed, while DexCom’s core CGM business reached about $4.0 billion in 2024, making these assets small and non-core.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eG5 Mobile\u003c\/td\u003e\n\u003ctd\u003eLegacy\u003c\/td\u003e\n\u003ctd\u003eOusted by G6\/G7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG4 Platinum\u003c\/td\u003e\n\u003ctd\u003eHarvest\u003c\/td\u003e\n\u003ctd\u003eNo growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEVEN Plus\u003c\/td\u003e\n\u003ctd\u003eDiscontinued\u003c\/td\u003e\n\u003ctd\u003eNo revenue tailwind\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReceiver hardware\u003c\/td\u003e\n\u003ctd\u003eFading\u003c\/td\u003e\n\u003ctd\u003eApp use rising\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVerily project\u003c\/td\u003e\n\u003ctd\u003eUnproven\u003c\/td\u003e\n\u003ctd\u003e0 disclosed revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom ONE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom ONE fits the Question Mark box: it targets price-sensitive markets and broader access use cases, but its share is still below DexCom’s core U.S. franchise. In DexCom, Inc.’s 2025 base, the business still leaned on the premium G7 line, so ONE’s growth runway is real, but dominance is not.\u003c\/p\u003e\n\u003cp\u003eThe category is attractive because CGM demand keeps widening, yet ONE still needs more scale, channel wins, and payer reach to turn that option into a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom ONE+ rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom ONE+ is a Question Mark in DexCom, Inc.’s BCG mix: it is built for newer international markets and lower-price segments, but share is still early. DexCom posted $4.03 billion in 2024 revenue, so ONE+ sits inside a larger, well-funded push. If rollout wins payer coverage and scale, it can move toward a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrediabetes CGM use cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrediabetes is a huge but early CGM pool: the CDC says 97.6 million U.S. adults had prediabetes, about 1 in 3, yet CGM use is still low. DexCom can win here by pushing education, OTC-style consumer access, and simpler onboarding, but today its share in this segment is still small. That makes prediabetes a classic Question Mark: big upside, weak current penetration, and unclear near-term payoff.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDirect-to-consumer diabetes prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom is still testing direct-to-consumer diabetes prevention, and penetration is low because CGM is mostly used through prescriptions. The U.S. has 97.6 million adults with prediabetes, so even small consumer adoption could matter, but the market is still unproven versus DexCom's about $4.03 billion 2024 revenue base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge prevention pool: 97.6 million prediabetes\u003c\/li\u003e\n\u003cli\u003eLow current consumer penetration\u003c\/li\u003e\n\u003cli\u003eFast growth if behavior change sticks\u003c\/li\u003e\n\u003cli\u003eStill a question mark, not a cash cow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext-gen Verily-based glucose monitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Verily-based glucose monitor is still a future bet for DexCom, not a scaled profit engine. It could widen DexCom beyond its core CGM line, but until it shows repeatable demand and clear revenue, it fits BCG Question Mark territory. DexCom’s core business already drives the cash, so this project needs proof, not hype.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFuture growth option, not scaled yet\u003c\/li\u003e\n\u003cli\u003eCould expand beyond current CGM formats\u003c\/li\u003e\n\u003cli\u003eNeeds traction before it turns into a Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom’s Growth Bets: Big Markets, Low Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom, Inc.’s Question Marks are ONE, ONE+, prediabetes, and future consumer glucose tools: all sit in big, growing markets, but current share is still low versus the core G7 franchise. DexCom’s $4.03 billion 2024 revenue shows the base is strong, yet these bets still need payer wins, scale, and adoption to move up the BCG grid.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDexcom ONE\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eLow share; price-led growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDexcom ONE+\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eEarly international rollout\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrediabetes\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003e97.6M U.S. adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191835566345,"sku":"dxcm-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/dxcm-bcg-matrix.webp?v=1783678486","url":"https:\/\/dcfanalyst.com\/products\/dxcm-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}